{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:02:21Z","timestamp":1761541341270,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/nrcardio.2016.167","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T10:12:22Z","timestamp":1475748742000},"page":"639-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["What have we learned from the ANTARCTIC trial?"],"prefix":"10.1038","volume":"13","author":[{"given":"Paul A.","family":"Gurbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"BFnrcardio2016167_CR1","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","volume":"118","author":"PA Gurbel","year":"2016","unstructured":"Gurbel, P. A., Jeong, Y. H., Navarese, E. P. & Tantry, U. S. Platelet-mediated thrombosis: from bench to bedside. Circ. Res. 118, 1380\u20131391 (2016).","journal-title":"Circ. Res."},{"key":"BFnrcardio2016167_CR2","doi-asserted-by":"publisher","unstructured":"Cayla, G.  et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomized controlled superiority trial. Lancet \n                    http:\/\/dx.doi.org\/10.1016\/S0140-6736(16)31323-X\n                    \n                   (2016).","DOI":"10.1016\/S0140-6736(16)31323-X"},{"key":"BFnrcardio2016167_CR3","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","volume":"46","author":"PA Gurbel","year":"2005","unstructured":"Gurbel, P. A.  et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46, 1820\u20131826 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016167_CR4","first-page":"844","volume":"115","author":"JL Reny","year":"2016","unstructured":"Reny, J. L.  et al. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb. Haemost. 115, 844\u2013855 (2016).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio2016167_CR5","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","volume":"51","author":"L Bonello","year":"2008","unstructured":"Bonello, L.  et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404\u20131411 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016167_CR6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"G Campo","year":"2010","unstructured":"Campo, G.  et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T\/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56, 1447\u20131455 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016167_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price, M. J.  et al. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097\u20131105 (2011).","journal-title":"JAMA"},{"key":"BFnrcardio2016167_CR8","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet, J. P.  et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100\u20132109 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2016167_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2013.05.023","volume":"62","author":"D Erlinge","year":"2013","unstructured":"Erlinge, D.  et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J. Am. Coll. Cardiol. 62, 577\u2013583 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016167_CR10","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1001\/jama.2012.17312","volume":"308","author":"PA Gurbel","year":"2012","unstructured":"Gurbel, P. A.  et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308, 1785\u20131794 (2012).","journal-title":"JAMA"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.167","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:58:05Z","timestamp":1684468685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2016.167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFnrcardio2016167"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2016.167","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"type":"print","value":"1759-5002"},{"type":"electronic","value":"1759-5010"}],"subject":[],"published":{"date-parts":[[2016,10,6]]},"assertion":[{"value":"6 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A.G. has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo\/Lilly, Haemonetics, Janssen Pharmaceuticals, Merck, and New Haven Pharmaceuticals; grants from Coramed Technologies, Duke Clinical Research Institute, Haemonetics, Harvard Clinical Research Institute, MedImmune, Merck, National Institutes of Health, New Haven Pharmaceuticals, and Sinnowa. He also owns a patent for platelet function testing, and stock options in Merck. U.S.T. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}